Zymeworks Inc

NYSE:ZYME   3:59:52 PM EDT
23.36
+0.26 (+1.13%)
4:00:00 PM EDT: $23.31 -0.05 (-0.21%)
Products, Regulatory

Zymeworks Presents Positive Phase 2 For Gastroesophageal Adenocarcinoma Treatment

Published: 09/16/2021 10:14 GMT
Zymeworks Inc (ZYME) - Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-line Her2-positive Gastroesophageal Adenocarcinoma (gea) at the European Society for Medical Oncology (esmo) Annual Congress.
Zymeworks Inc - Confirmed Objective Response Rate (corr) of 75% Overall and 93% for Proposed Phase 3 Regimen.
Zymeworks Inc - Median Duration of Response of 16.4 Months and Median Progression Free Survival (mpfs) of 12 Months.
Zymeworks Inc - Global Randomized Phase 3 Trial Scheduled to Launch in Q4 of 2021.